Here we established that SRI31215, and peptide-based inhibitors of pro-HGF activation, block the tumor-promoting activity of fibroblasts and overcome the resistance of MET-amplified lung cancer cells to anti-MET therapy (Figures 3 and 4). The gene discussed is HGF; the disease is lung carcinoma.